Advances in tenascin-C biology

Cellular and Molecular Life Sciences

Volumn 68, Issue 19, 2011, Pages 3175-3199

  Midwood, Kim S ^a   Hussenet, Thomas ^b   Langlois, Benoit ^b   Orend, Gertraud ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Cardiac injury; Stem cells; Tenascin C; Tumor metastasis; Vascular imaging

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOXORUBICIN; GELATINASE B; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; NANOPARTICLE; NEURADIAB; PACLITAXEL; PROTEIN ANTIBODY; SMALL INTERFERING RNA; TAMOXIFEN; TEMOZOLOMIDE; TENASCIN; TENASCIN C ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADJUVANT THERAPY; ARTERY INJURY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN TUMOR; BREAST CANCER; CANCER INVASION; CANCER STEM CELL; CARCINOGENESIS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CYTOLOGY; DISEASE COURSE; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HEART INJURY; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA CELL; NEURAL STEM CELL; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PROLACTIN BLOOD LEVEL; PROTEIN DEFECT; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SMOOTH MUSCLE FIBER; STEM CELL; STEM CELL MOBILIZATION; THROMBOSIS; TISSUE REGENERATION; TISSUE REPAIR; TUMOR CELL; TUMOR VASCULARIZATION; WOUND HEALING;

ANIMALS; ATHEROSCLEROSIS; GENE EXPRESSION REGULATION; HUMANS; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, SMOOTH MUSCLE; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; RATS; STEM CELLS; TENASCIN; VASCULAR DISEASES; WOUND HEALING;

EID: 80052942375     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0783-6     Document Type: Review

References (201)

1. Midwood KS, Orend G (2009) The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 3(3-4): 287-310
2. Orend G (2005) Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 37(5):1066-1083 (Pubitemid 40311747)
3. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG (2010) The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 48(3):504-511
4. Imanaka-Yoshida K, Hiroe M, Yoshida T (2004) Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 19(2):517-525 (Pubitemid 38443913)
5. Imanaka-Yoshida K et al (2003) The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation 71(4-5):291-298 (Pubitemid 36819114)
6. Forsberg E et al (1996) Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci USA 93(13):6594-6599 (Pubitemid 26230353)
7. Saga Y et al (1992) Mice develop normally without tenascin. Genes Dev 6(10):1821-1831
8. Willems IE, Arends JW, Daemen MJ (1996) Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 179(3):321-325 (Pubitemid 26266413)
9. Sato I, Shimada K (2001) Quantitative analysis of tenascin in chordae tendineae of human left ventricular papillary muscle with aging. Ann Anat 183(5):443-448 (Pubitemid 32923196)
10. Laky D, Parascan L (2007) Hibernating myocardium, morphological studies on intraoperatory myocardial biopsies and on chronic ischemia experimental model. Rom J Morphol Embryol 48(4):407-413
11. Duerr GD et al (2011) Comparison of myocardial remodeling between cryoinfarction and reperfused infarction in mice. J Biomed Biotechnol 961298
12. Taki J et al (2010) Dynamic expression of tenascin-C after myocardial ischemia and reperfusion: assessment by 125I-antitenascin- C antibody imaging. J Nucl Med 51(7):1116-1122
13. Imanaka-Yoshida K et al (2002) Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 197(3):388-394 (Pubitemid 34778310)
14. Sato M et al (2002) Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation 106(11):1397-1402 (Pubitemid 35013045)
15. Correia-Pinto J et al (2009) Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotalineinduced pulmonary hypertension. Basic Res Cardiol 104(5): 535-545
16. Hessel M et al (2009) Pressure overload-induced right ventricular failure is associated with re-expression of myocardial tenascin-C and elevated plasma tenascin-C levels. Cell Physiol Biochem 24(3-4):201-210
17. Suzuki H et al (2010) Tenascin-C is induced in cerebral vasospasm after subarachnoid hemorrhage in rats and humans: a pilot study. Neurol Res 32(2):179-184
18. Franz M et al (2010) Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A ? fibronectin, alpha-smooth muscle actin and B ? tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol 134(5):503-517
19. Schenke-Layland K et al (2009) Cardiomyopathy is associated with structural remodelling of heart valve extracellular matrix. Eur Heart J 30(18):2254-2265
20. Morimoto S et al (2005) Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 205(4):460-467 (Pubitemid 40361334)
21. Tsukada B et al (2009) High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation. Hum Pathol 40(7):1015-1022
22. Tamura A et al (1996) Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart 75(3):291-294 (Pubitemid 26094968)
23. Sato A et al (2006) Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 47(11):2319-2325 (Pubitemid 43795072)
24. Terasaki F et al (2007) Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 71(3):327-330 (Pubitemid 46409533)
25. Fujimoto N et al (2009) Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Card Fail 15(10):898-905
26. Aso N, Tamura A, Nasu M (2004) Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 94(11):1468-1470 (Pubitemid 39556230)
27. Liabeuf S et al (2011) High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. Atherosclerosis 215(1): 116-124
28. Hessel MH et al (2007) Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail 9(10):1058-1063 (Pubitemid 47451814)
29. Nishioka T et al (2007) Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 49(5):261-268 (Pubitemid 46855118)
30. Siri A et al (1995) Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 270(15):8650-8654
31. Chiao YA et al (2010) In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics. J Proteome Res 9(5):2649-2657
32. Zamilpa R et al (2010) Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics 10(11):2214-2223
33. Saito Y et al (2007) A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J Biol Chem 282(48):34929-34937 (Pubitemid 350232444)
34. Ambort D et al (2010) Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading. Matrix Biol 29(1):31-42
35. To WS, Midwood KS (2010) Cryptic domains of tenascin-C differentially control fibronectin fibrillogenesis. Matrix Biol 29(7):573-585
36. To WS, Midwood KS (2011) Identification of novel and distinct binding sites within tenascin-C for soluble and fibrillar fibronectin. J Biol Chem 286(17):14881-14891
37. Tucker RP, Chiquet-Ehrismann R (2009) The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta 1793(5):888-892
38. Chiquet M et al (2009) From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim Biophys Acta 1793(5):911-920
39. Yamamoto K et al (1999) Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J Biol Chem 274(31):21840-21846
40. Jiang L et al (2009) Synergistic effects of cyclic strain and Th1- like cytokines on tenascin-C production by rheumatic aortic valve interstitial cells. Clin Exp Immunol 155(2):216-223
41. Chiquet-Ehrismann R, Chiquet M (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol 200(4):488-499 (Pubitemid 36818249)
42. Chiquet-Ehrismann R et al (1988) Tenascin interferes with fibronectin action. Cell 53(3):383-390
43. Huang W et al (2001) Interference of tenascin-C with syndecan- 4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 61(23):8586-8594 (Pubitemid 33131143)
44. Murphy-Ullrich JE et al (1991) Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 115(4):1127-1136 (Pubitemid 21909959)
45. Orend G et al (2003) Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 22(25):3917-3926 (Pubitemid 36819665)
46. Imanaka-Yoshida K et al (2001) Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 81(7):1015-1024 (Pubitemid 32645977)
47. Udalova IA et al. (2011) Expression and immune function of tenascin-C. Crit Rev Immunol 31(2):115-145
48. Midwood K et al (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15(7):774-780
49. Kanayama M et al (2009) Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol 182(12):8015-8025
50. Hanamura N et al (1997) Expression of fibronectin and tenascin- C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 73(1):10-15 (Pubitemid 27445983)
51. Kalembeyi I et al (2003) Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer 105(1):53-60 (Pubitemid 36418485)
52. Yoshida T et al (1997) Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol 182(4):421-428 (Pubitemid 27317207)
53. Berndt A et al (1994) Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 62(2):55-58 (Pubitemid 24215140)
54. Tamaoki M et al (2005) Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 167(1):71-80 (Pubitemid 40884771)
55. Nishioka T et al (2010) Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 298(3):H1072-H1078
56. Bujak M et al (2007) Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 116(19):2127-2138 (Pubitemid 350060350)
57. Huang Z et al (2009) Defective pulmonary vascular remodeling in Smad8 mutant mice. Hum Mol Genet 18(15):2791-2801
58. El-Karef A et al (2007) Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 211(1):86-94 (Pubitemid 46092033)
59. Nakao N et al (1998) Tenascin-C promotes healing of Habusnake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. Am J Pathol 152(5):1237-1245 (Pubitemid 28221876)
60. Shah M, Foreman DM, Ferguson MW (1994) Neutralising antibody to TGF-beta 1, 2 reduces cutaneous scarring in adult rodents. J Cell Sci 107(Pt 5):1137-1157
61. Shah M, Foreman DM, Ferguson MW (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108(Pt 3):985-1002
62. Hedin U, Holm J, Hansson GK (1991) Induction of tenascin in rat arterial injury. Relationship to altered smooth muscle cell phenotype. Am J Pathol 139(3):649-656
63. Yamamoto K et al (2005) Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardiovasc Res 65(3):737-742 (Pubitemid 40138995)
64. Sawada Y et al (2007) Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis. Cardiovasc Res 74(3):366-376 (Pubitemid 46693714)
65. von Lukowicz T et al (2007) Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med 48(4):582-587 (Pubitemid 47571414)
66. Jones PL, Rabinovitch M (1996) Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 79(6):1131-1142 (Pubitemid 26404145)
67. Wallner K et al (1999) Tenascin-C is expressed in macrophagerich human coronary atherosclerotic plaque. Circulation 99(10):1284-1289 (Pubitemid 29129911)
68. Kenji K et al (2004) Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes. Circ J 68(3):198-203
69. Seo D et al (2004) Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 24(10):1922-1927 (Pubitemid 39350314)
70. Qin M et al (2003) Suppression subtractive hybridization identifies distinctive expression markers for coronary and internal mammary arteries. Arterioscler Thromb Vasc Biol 23(3): 425-433 (Pubitemid 36337218)
71. Fukumoto H et al (1998) Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J Atheroscler Thromb 5(1):29-35
72. Duner P et al (2009) Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease. J Intern Med 265(5):593-603
73. Minear MA et al (2011) Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease. Hum Genet 129(6):641-654
74. Pitman WA et al (1998) Genetic analysis of the difference in diet-induced atherosclerosis between the inbred mouse strains SM/J and NZB/BINJ. Arterioscler Thromb Vasc Biol 18(4): 615-620 (Pubitemid 28177902)
75. Wallner K et al (1999) Arterialization of human vein grafts is associated with tenascin-C expression. J Am Coll Cardiol 34(3):871-875 (Pubitemid 29436196)
76. Imanaka-Yoshida K et al (2001) Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: clinical significance of early tenascin-C expression. Virchows Arch 439(2):185-190 (Pubitemid 32758912)
77. Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 295(8):420-425
78. Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 295(7):369-377
79. Goh FG et al (2010) Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 184(5):2655-2662
80. Wallner K et al (2001) Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts. J Am Coll Cardiol 37(2):655-661
81. Sharifi BG et al (1992) Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. J Biol Chem 267(33):23910-23915 (Pubitemid 23088203)
82. Wallner K, Shah PK, Sharifi BG (2002) Balloon catheterization induces arterial expression of new Tenascin-C isoform. Atherosclerosis 161(1):75-83 (Pubitemid 34214823)
83. Feng Y et al (1999) Transcriptional profile of mechanically induced genes in human vascular smooth muscle cells. Circ Res 85(12):1118-1123 (Pubitemid 30430615)
84. Jones PL et al (2002) Altered hemodynamics controls matrix metalloproteinase activity and tenascin-C expression in neonatal pig lung. Am J Physiol Lung Cell Mol Physiol 282(1):L26-L35 (Pubitemid 34654177)
85. Jones PL et al (1999) Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. J Cell Sci 112(Pt 4):435-445 (Pubitemid 29106191)
86. Jones FS et al (2001) Prx1 controls vascular smooth muscle cell proliferation and tenascin-C expression and is upregulated with Prx2 in pulmonary vascular disease. Circ Res 89(2):131-138 (Pubitemid 34135820)
87. Chapados R et al (2006) ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling. Circ Res 99(8):837-844 (Pubitemid 44556382)
88. LaFleur DW et al (1997) Aortic smooth muscle cells interact with tenascin-C through its fibrinogen-like domain. J Biol Chem 272(52):32798-32803
89. Yokoyama K et al (2000) Identification of amino acid sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3. J Biol Chem 275(22):16891-16898 (Pubitemid 30398926)
90. LaFleur DW et al (1994) Cloning and characterization of alternatively spliced isoforms of rat tenascin. Platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. J Biol Chem 269(32):20757-20763
91. Jones PL, Cowan KN, Rabinovitch M (1997) Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 150(4):1349-1360 (Pubitemid 27152653)
92. Jones PL, Crack J, Rabinovitch M (1997) Regulation of tenascin- C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 139(1):279-293 (Pubitemid 27444098)
93. Ishigaki T et al(2010) Tenascin-C enhances crosstalk signaling of integrin alphavbeta3/PDGFR-beta complex by SRC recruitment promoting PDGF-induced proliferation and migration in smooth muscle cells. J Cell Physiol. doi:10.1002/jcp.22614
94. Watkins H, Farrall M (2006) Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 7(3): 163-173 (Pubitemid 43361528)
95. Wallner K et al (2004) EGF-Like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 24(8):1416-1421 (Pubitemid 39050434)
96. Fujinaga K et al (2004) Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg 128(3):357-363 (Pubitemid 39194689)
97. Cowan KN, Jones PL, Rabinovitch M (2000) Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin- C antisense prevents progression, of vascular disease. J Clin Invest 105(1):21-34 (Pubitemid 30036384)
98. Schaff M et al (2010) Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol 31(1):117-124
99. Brellier F et al (2011) Tenascin-C triggers fibrin accumulation by downregulation of tissue plasminogen activator. FEBS Lett 585(6):913-920
100. Cowan KN, Jones PL, Rabinovitch M (1999) Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 84(10): 1223-1233 (Pubitemid 29244784)
101. Jian B et al (2001) Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 159(1): 321-327 (Pubitemid 33704217)
102. Vyavahare N et al (2000) Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats. Am J Pathol 157(3):885-893 (Pubitemid 32109381)
103. Garcion E, Faissner A, ffrench-Constant C (2001) Knockout mice reveal a contribution of the extracellular matrix molecule tenascin-C to neural precursor proliferation and migration. Development 128(13):2485-2496 (Pubitemid 32685090)
104. Garcion E et al (2004) Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development 131(14):3423-3432 (Pubitemid 39139888)
105. Abaskharoun M et al (2010) Glypican-1, phosphacan/receptor protein-tyrosine phosphatase-zeta/beta and its ligand, tenascin- C, are expressed by neural stem cells and neural cells derived from embryonic stem cells. ASN Neuro 2(3):e00039
106. von Holst A et al (2007) Neural stem/progenitor cells express 20 tenascin C isoforms that are differentially regulated by Pax6. J Biol Chem 282(12):9172-9181 (Pubitemid 47093541)
107. Yagi H et al (2010) HNK-1 epitope-carrying tenascin-C spliced variant regulates the proliferation of mouse embryonic neural stem cells. J Biol Chem 285(48):37293-37301
108. Moritz S et al (2008) An induction gene trap screen in neural stem cells reveals an instructive function of the niche and identifies the splicing regulator sam68 as a tenascin-C-regulated target gene. Stem Cells 26(9):2321-2331
109. Najib S et al (2005) Role of Sam68 as an adaptor protein in signal transduction. Cell Mol Life Sci 62(1):36-43 (Pubitemid 40933090)
110. Bielli P et al (2011) The RNA binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer 18(4):R91-R102
111. Czopka T et al (2010) Regulatory mechanisms that mediate tenascin C-dependent inhibition of oligodendrocyte precursor differentiation. J Neurosci 30(37):12310-12322
112. Ricci-Vitiani L et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325):824-828
113. Wang R et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829-833
114. Pezzolo A et al (2011) Oct-4(?)/Tenascin C(?) neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res. Mar 15 Epub ahead of print
115. Fukunaga-Kalabis M et al (2010) Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 29(46):6115-6124
116. Mackie EJ et al (1987) Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 84(13):4621-4625
117. Adams M et al (2002) Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 62(11):3289-3297 (Pubitemid 34602427)
118. Tsunoda T et al (2003) Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 162(6): 1857-1867 (Pubitemid 36613044)
119. Hancox RA et al (2009) Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11(2):R24
120. Guttery DS et al Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res 12(4): R57
121. Minn AJ et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518-524 (Pubitemid 41112921)
122. Tavazoie SF et al (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175):147-152
123. Scharer CD et al (2009) Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 69(2):709-717
124. Taraseviciute A et al (2010) Quantitative analysis of threedimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am J Pathol 176(2):827-838
125. Helleman J et al (2008) Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 14(17):5555-5564
126. Leins A et al (2003) Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98(11):2430-2439 (Pubitemid 37466658)
127. Herold-Mende C et al (2002) Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 98(3):362-369 (Pubitemid 34188679)
128. Colman H et al (2011) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12(1):49-57
129. Brellier F et al (2010) SMOC1 is a tenascin-C interacting protein over-expressed in brain tumors. Matrix Biol 30(3):225-233
130. Hirata E et al (2009) Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci 100(8):1451-1459
131. Sarkar S et al (2006) Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 66(24): 11771-11780 (Pubitemid 46094189)
132. Sarkar S, Yong VW (2010) Reduction of protein kinase C delta attenuates tenascin-C stimulated glioma invasion in threedimensional matrix. Carcinogenesis 31(2):311-317
133. Sivasankaran B et al (2009) Tenascin-C is a novel RBPJkappainduced target gene for Notch signaling in gliomas. Cancer Res 69(2):458-465
134. Lyons AJ, Jones J (2007) Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int J Oral Maxillofac Surg 36(8):671-679 (Pubitemid 47091508)
135. Atula T et al (2003) Tenascin-C expression and its prognostic significance in oral and pharyngeal squamous cell carcinoma. Anticancer Res 23(3C):3051-3056 (Pubitemid 36969859)
136. Wang Z et al (2011) Expression of angiopoietin-like 4 and tenascin C but not cathepsin C mRNA predicts prognosis of oral tongue squamous cell carcinoma. Biomarkers 15(1):39-46
137. Pazzaglia L et al (2010) Differential gene expression in classic giant cell tumours of bone: tenascin C as biological risk factor for local relapses and metastases. Histopathology 57(1): 59-72
138. Schliemann C et al (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33(12):1718-1722
139. Berndt A et al (2010) A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol 133(4):467-475
140. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674
141. Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis. Semin Cancer Biol 19(5):329-337
142. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417-427
143. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5(6):436-446 (Pubitemid 40791486)
144. Brack SS et al (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12(10):3200-3208 (Pubitemid 43837370)
145. Martina E et al (2010) Tenascin-W is a specific marker of glioma- associated blood vessels and stimulates angiogenesis in vitro. FASEB J 24(3): 778-787
146. Borgia B et al (2010) A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Res 70(1):309-318
147. Hill JJ et al (2011) Identification of vascular breast tumor markers by laser capture microdissection and label-free LC-MS. J Proteome Res 10(5):2479-2493
148. Sumioka T et al (2011) Impaired angiogenic response in the cornea of mice lacking tenascin C. Invest Ophthalmol Vis Sci 52(5):2462-2467
149. Bicer A et al (2010) Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vascular malformations. J Clin Neurosci 17(2):232-236
150. Ballard VL et al (2006) Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J 20(6):717-719 (Pubitemid 46671192)
151. Tanaka K et al (2004) Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int J Cancer 108(1):31-40 (Pubitemid 37444440)
152. Lange K et al (2007) Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res 67(13):6163-6173 (Pubitemid 47037497)
153. Lange K et al (2008) Combined lysophosphatidic acid/plateletderived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res 68(17):6942-6952
154. Vouret-Craviari V et al (2004) ILK is required for the assembly of matrix-forming adhesions and capillary morphogenesis in endothelial cells. J Cell Sci 117(Pt 19):4559-4569 (Pubitemid 39360081)
155. Hynes RO (2009) The extracellular matrix: not just pretty fibrils. Science 326(5957):1216-1219
156. Paasinen-Sohns A et al (2011) Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing Sadenosylmethionine decarboxylase. Int J Biochem Cell Biol 43(3):441-454
157. Gebb SA, Jones PL (2003) Hypoxia and lung branching morphogenesis. Adv Exp Med Biol 543:117-125 (Pubitemid 38183719)
158. Koperek O et al (2011) Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene. J Pathol 225(1):63-72
159. Dejana E (2010) The role of Wnt signaling in physiological and pathological angiogenesis. Circ Res 107(8):943-952
160. Stefater Iii JA et al (2011) Regulation of angiogenesis by a noncanonical Wnt-Flt1 pathway in myeloid cells. Nature 474: 511-515
161. Ruiz C et al (2004) Growth promoting signaling by tenascin-C [corrected]. Cancer Res 64(20):7377-7385
162. Brellier F et al (2011) Tenascin-C triggers fibrin accumulation by downregulation of tissue plasminogen activator. FEBS Lett 585(6):913-920
163. El Hallani S et al (2010) A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133(Pt 4): 973-982
164. Onishi M et al (2011) Angiogenesis and invasion in glioma. Brain Tumor Pathol 28(1): 13-24
165. Lino M, Merlo A (2009) Translating biology into clinic: the case of glioblastoma. Curr Opin Cell Biol 21(2):311-316
166. Kaariainen E et al (2006) Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen- I forming specific channel structures for invasion. J Pathol 210(2):181-191 (Pubitemid 44463933)
167. Hendrix MJ et al (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3(6):411-421 (Pubitemid 37328845)
168. Lokmic Z et al (2008) The extracellular matrix of the spleen as a potential organizer of immune cell compartments. Semin Immunol 20(1):4-13
169. Link A et al (2011) Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am J Pathol 178(4): 1662-1675
170. Drumea-Mirancea M et al (2006) Characterization of a conduit system containing laminin-5 in the human thymus: a potential transport system for small molecules. J Cell Sci 119(Pt 7): 1396-1405
171. Sobocinski GP et al (2010) Ultrastructural localization of extracellular matrix proteins of the lymph node cortex: evidence supporting the reticular network as a pathway for lymphocyte migration. BMC Immunol 11:42
172. Gaggioli C et al (2007) Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9(12):1392-1400 (Pubitemid 350201752)
173. Wolf K et al (2007) Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 9(8):893-904 (Pubitemid 47190444)
174. Lugassy C, Barnhill RL (2007) Angiotropic melanoma and extravascular migratory metastasis: a review. Adv Anat Pathol 14(3):195-201 (Pubitemid 46659190)
175. Talts JF et al (1999) Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci 112(Pt 12):1855-1864 (Pubitemid 29338811)
176. Nakahara H et al (2006) Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 36(12):3334-3345 (Pubitemid 44932735)
177. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71-78 (Pubitemid 38082155)
178. Silacci M et al (2006) Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 19(10):471-478 (Pubitemid 44408907)
179. Reardon DA et al (2008) A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 10(2):182-189
180. Zalutsky MR et al (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49(1):30-38
181. Rolle K et al (2010) Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol Ther 9(5):396-406
182. Schwager K et al (2011) A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol 3:25
183. Pedretti M et al (2009) Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 64(1):28-33
184. Schwager K et al (2011) A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol 3:25
185. Marlind J et al (2008) Antibody-mediated delivery of interleukin- 2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14(20):6515-6524
186. Ko HY et al (2011) A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin alphavbeta3 and tenascin-C proteins. Biomaterials 32(4): 1130-1138
187. Odaka K et al (2008) Noninvasive detection of cardiac repair after acute myocardial infarction in rats by 111 In Fab fragment of monoclonal antibody specific for tenascin-C. Int Heart J 49(4):481-492
188. Meding J et al (2007) Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. Contrast Media Mol Imaging 2(3):120-129 (Pubitemid 47180344)
189. Pedretti M et al (2010) Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinical-grade fully human antibodies. Atherosclerosis 208(2):382-389
190. Madhavan S et al (2009) Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 7(2):157-167
191. Celik A et al (2011) Tenascin-C may be a predictor of acute pulmonary thromboembolism. J Atheroscler Thromb 18(6): 487-493
192. Majumdar R et al (2007) Elevated expressions of osteopontin and tenascin C in ascending aortic aneurysms are associated with trileaflet aortic valves as compared with bicuspid aortic valves. Cardiovasc Pathol 16(3):144-150 (Pubitemid 46729667)
193. Della Corte A et al (2008) Spatiotemporal patterns of smooth muscle cell changes in ascending aortic dilatation with bicuspid and tricuspid aortic valve stenosis: focus on cell-matrix signaling. J Thorac Cardiovasc Surg 135(1): 8-18, 18 e1-2
194. Franz M et al (2009) Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 11(11):1057-1062
195. Milting H et al (2008) Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 27(6):589-596 (Pubitemid 351715387)
196. Frangogiannis NG et al (2002) Active interstitial remodeling: an important process in the hibernating human myocardium. J Am Coll Cardiol 39(9):1468-1474 (Pubitemid 34439062)
197. Donato G et al (2009) Expression of tenascin-C and CD44 receptors in cardiac myxomas. Cardiovasc Pathol 18(3):173-177
198. Schumann C et al (2010) Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers 15(6): 523-532
199. Franz M et al (2010) Changes in extra cellular matrix remodeling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. J Mol Histol 41(1):39-50
200. Pedretti M et al (2010) Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 103(6):827-836
201. Ko HY et al (2011) A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin alphavbeta3 and tenascin-C proteins. Biomaterials 32(4): 1130-1138